Physician profile
Michael E Snyder
NPI 1720075682
$215,733.60
in general payments reported to CMS, 2019-2025
24 companies · $13K in 2025
The $13K reported for 2025 was more than what 96% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93K · 2020: $73K · 2021: $1,369 · 2022: $6,118 · 2023: $6,321 · 2024: $22K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $36K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Food and Beverage: $2,170 · Grant: $750 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $35,517.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Food and Beverage | $2,170.35 |
| Grant | $750.00 |
| Education | $120.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Haag-Streit USA, INC. | $193,808.99 | 2019-2025 | |
| W. L. Gore & Associates, INC. | $18,025.25 | 2019-2025 | Product In Development |
| Beaver-Visitec International, INC. | $1,303.15 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $822.71 | 2021-2025 | Tecnis Iol, Tecnis Simplicity |
| Alcon Vision LLC | $259.16 | 2019-2025 | Centurion, Clareon |
| Dompe US, INC. | $211.29 | 2024-2025 | Oxervate |
| Rxsight INC | $193.73 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Harrow Eye, LLC | $176.47 | 2025 | Vevye |
| Bausch & Lomb Americas INC. | $150.92 | 2023 | Envista Mx60 Iol, Stellaris |
| Dutch Ophthalmic, USA | $149.93 | 2024 | Eva, Combined Machine, Tissueblue |
| Mallinckrodt Hospital Products INC. | $134.73 | 2025 | Acthar |
| Ivantis, INC | $120.13 | 2019 | |
| Samsara Vision | $115.38 | 2025 | Implantable Miniature Telescope (Imt By Dr. Isaac Lipshitz) |
| Ocular Therapeutix, INC. | $100.00 | 2019 | |
| Biotissue Holdings INC. | $39.59 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $37.13 | 2023-2024 | Lumigan, Alphagan P, Vuity |
| Sun Pharmaceutical Industries INC. | $24.39 | 2025 | |
| Janssen Pharmaceuticals, INC | $19.11 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.99 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $12.64 | 2019 | |
| Genentech USA, INC. | $11.91 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$165,250.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.